Headquartered in Baarerstrasse 14, ZUG Fiscal year ends December NASDAQ: CRSP crisprtx.com
CRISPR Therapeutics is a biopharmaceutical company focused on developing gene-based medicines for serious human diseases using CRISPR/Cas9 and its proprietary SyNTase editing technology. The company's first approved product, CASGEVY (exagamglogene autotemcel), is the world's first CRISPR-based therapy, developed in collaboration with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia, and is approved in 39 countries. Under the Vertex collaboration, CRISPR Therapeutics shares profits and costs on a 40/60 basis. Beyond hemoglobinopathies, the company is advancing a diversified pipeline spanning in vivo liver-directed gene editing programs (CTX310 for dyslipidemia, CTX340 for hypertension, CTX321 for elevated Lp(a), and CTX460 for alpha-1 antitrypsin deficiency), allogeneic CAR-T cell therapies (zugo-cel for autoimmune diseases and B-cell malignancies), siRNA therapeutics through its Sirius Therapeutics collaboration (CTX611 targeting Factor XI for thromboembolic diseases), in vivo CAR-T platforms, and regenerative medicine programs including a deviceless beta cell replacement candidate for Type 1 diabetes. The company operates a wholly-owned GMP manufacturing facility in Framingham, Massachusetts, supporting its cell therapy portfolio across clinical and future commercial supply. Updated
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug…
Most asset managers try to track the market. Through ARK Investment, Cathie Wood is trying to get ahead of the market’s best ideas by identifying disruptive innovation early, even when the underlying…
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots…
What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible? The personalized biotech…
CRISPR Therapeutics (NASDAQ:CRSP | CRSP Price Prediction) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday…
Joel South While insider buying has been slow lately, there have been some notable, large purchases at a couple of biotech companies, and e-commerce company.
Insiders have become bearish. In fact, according to MarketWatch, “Corporate insiders have taken a sharply pessimistic turn – selling their companies’ shares at the fastest rate in at least a decade.” Plus,…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Pfizer (NYSE:PFE | PFE Price Prediction) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster…
The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The tech sector has been the driving force for the stock market’s gains…
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT | WMT Price Prediction)…
Cathie Wood is the founder and CEO of Ark Invest, an asset management firm focusing on disruptive innovation, with approximately $14 billion in assets across six actively managed ETFs, two index ETFs,…
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery process is…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
CRISPR Therapeutics is a biopharmaceutical company focused on developing gene-based medicines for serious human diseases using CRISPR/Cas9 and its proprietary SyNTase editing technology.
24/7 Wall St.'s 12-month price target for CRSP is $103.76, rated Buy. The Wall Street consensus target is $87.56. CRSP price prediction →
